BR112019004504A2 - anticorpo monoclonal ou fragmento de ligação do mesmo, molécula, vetor, célula, método para produzir um anticorpo ou fragmento de ligação, composição, e, uso da composição - Google Patents
anticorpo monoclonal ou fragmento de ligação do mesmo, molécula, vetor, célula, método para produzir um anticorpo ou fragmento de ligação, composição, e, uso da composiçãoInfo
- Publication number
- BR112019004504A2 BR112019004504A2 BR112019004504A BR112019004504A BR112019004504A2 BR 112019004504 A2 BR112019004504 A2 BR 112019004504A2 BR 112019004504 A BR112019004504 A BR 112019004504A BR 112019004504 A BR112019004504 A BR 112019004504A BR 112019004504 A2 BR112019004504 A2 BR 112019004504A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- binding fragment
- composition
- human
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
Abstract
é provido um novo anticorpo. de acordo com a presente invenção, um anticorpo monoclonal ou um fragmento de ligação do mesmo liga-se ao domínio 3 de uma lag-3 humana e tem as propriedades descritas em (i) e (vi) e uma ou mais das propriedades descritas em (ii) a (v) abaixo: (i) o anticorpo tem atividade de adcc in vitro; (ii) o anticorpo é um anticorpo com baixo teor de fucose e reduz o número de células positivas para lag-3 in vivo; (iii) o anticorpo é um anticorpo com baixo teor de fucose e suprime a encefalomielite autoimune experimental in vivo; (iv) a lag-3 humana se liga a uma célula t ativada humana; (v) a lag-3 humana se liga a uma molécula do complexo principal de genes de histocompatibilidade humana de classe ii na presença do anticorpo ou de um fragmento de ligação do mesmo; e (vi) a lag-3 humana apresenta uma função de supressão de células t humanas na presença do anticorpo ou de um fragmento de ligação do mesmo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016175491 | 2016-09-08 | ||
PCT/JP2017/032212 WO2018047894A1 (ja) | 2016-09-08 | 2017-09-07 | 自己免疫疾患治療用抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019004504A2 true BR112019004504A2 (pt) | 2019-09-03 |
Family
ID=61562465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019004504A BR112019004504A2 (pt) | 2016-09-08 | 2017-09-07 | anticorpo monoclonal ou fragmento de ligação do mesmo, molécula, vetor, célula, método para produzir um anticorpo ou fragmento de ligação, composição, e, uso da composição |
Country Status (16)
Country | Link |
---|---|
US (2) | US20190202911A1 (pt) |
EP (1) | EP3511414A4 (pt) |
JP (3) | JP6865758B2 (pt) |
KR (1) | KR102538723B1 (pt) |
CN (1) | CN109689870B (pt) |
AU (1) | AU2017325272A1 (pt) |
BR (1) | BR112019004504A2 (pt) |
CA (1) | CA3036350A1 (pt) |
CO (1) | CO2019002477A2 (pt) |
IL (1) | IL265178A (pt) |
MX (1) | MX2019002742A (pt) |
MY (1) | MY190805A (pt) |
PH (1) | PH12019500482A1 (pt) |
SG (1) | SG10201912764TA (pt) |
TW (1) | TWI801350B (pt) |
WO (1) | WO2018047894A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201927336A (zh) * | 2017-10-05 | 2019-07-16 | 日商第一三共股份有限公司 | 細胞毒性t細胞耗竭用組成物 |
US11793889B2 (en) * | 2018-09-24 | 2023-10-24 | Kinase Pharma Inc. | Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases |
KR102063341B1 (ko) * | 2018-12-31 | 2020-01-07 | 다이노나(주) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
KR101088178B1 (ko) | 2009-12-18 | 2011-12-02 | 한국과학기술원 | 멀티 라디오 모바일 애드 혹 네트워크 환경에서의 라우팅 방법 |
AU2014230741B2 (en) * | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
KR102081232B1 (ko) | 2013-05-28 | 2020-02-25 | 에스케이플래닛 주식회사 | 태그 정보를 이용한 컨텐츠 생성 지원을 위한 장치 |
TWI777174B (zh) * | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
-
2017
- 2017-09-07 CN CN201780055062.4A patent/CN109689870B/zh active Active
- 2017-09-07 AU AU2017325272A patent/AU2017325272A1/en active Pending
- 2017-09-07 CA CA3036350A patent/CA3036350A1/en active Pending
- 2017-09-07 EP EP17848832.6A patent/EP3511414A4/en active Pending
- 2017-09-07 JP JP2018538460A patent/JP6865758B2/ja active Active
- 2017-09-07 SG SG10201912764TA patent/SG10201912764TA/en unknown
- 2017-09-07 WO PCT/JP2017/032212 patent/WO2018047894A1/ja unknown
- 2017-09-07 TW TW106130563A patent/TWI801350B/zh active
- 2017-09-07 US US16/331,171 patent/US20190202911A1/en active Pending
- 2017-09-07 KR KR1020197006723A patent/KR102538723B1/ko active IP Right Grant
- 2017-09-07 MY MYPI2019000598A patent/MY190805A/en unknown
- 2017-09-07 BR BR112019004504A patent/BR112019004504A2/pt unknown
- 2017-09-07 MX MX2019002742A patent/MX2019002742A/es unknown
-
2019
- 2019-03-05 PH PH12019500482A patent/PH12019500482A1/en unknown
- 2019-03-05 IL IL265178A patent/IL265178A/en unknown
- 2019-03-15 CO CONC2019/0002477A patent/CO2019002477A2/es unknown
- 2019-11-07 US US16/677,506 patent/US10647769B1/en active Active
-
2021
- 2021-04-06 JP JP2021064662A patent/JP7269981B2/ja active Active
-
2023
- 2023-04-24 JP JP2023070525A patent/JP2023089273A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019110133A3 (pt) | 2020-12-18 |
CA3036350A1 (en) | 2018-03-15 |
MX2019002742A (es) | 2019-05-09 |
PH12019500482A1 (en) | 2019-06-03 |
TWI801350B (zh) | 2023-05-11 |
EP3511414A4 (en) | 2020-11-18 |
US10647769B1 (en) | 2020-05-12 |
JPWO2018047894A1 (ja) | 2019-07-11 |
JP7269981B2 (ja) | 2023-05-09 |
AU2017325272A2 (en) | 2019-04-18 |
IL265178A (en) | 2019-05-30 |
US20190202911A1 (en) | 2019-07-04 |
KR102538723B1 (ko) | 2023-05-31 |
EP3511414A1 (en) | 2019-07-17 |
KR20190045208A (ko) | 2019-05-02 |
US20200123253A1 (en) | 2020-04-23 |
SG10201912764TA (en) | 2020-02-27 |
WO2018047894A1 (ja) | 2018-03-15 |
CN109689870B (zh) | 2022-11-29 |
TW201811366A (zh) | 2018-04-01 |
AU2017325272A1 (en) | 2019-04-04 |
JP6865758B2 (ja) | 2021-04-28 |
JP2021105040A (ja) | 2021-07-26 |
MY190805A (en) | 2022-05-12 |
RU2019110133A (ru) | 2020-10-08 |
CN109689870A (zh) | 2019-04-26 |
JP2023089273A (ja) | 2023-06-27 |
CO2019002477A2 (es) | 2019-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019004504A2 (pt) | anticorpo monoclonal ou fragmento de ligação do mesmo, molécula, vetor, célula, método para produzir um anticorpo ou fragmento de ligação, composição, e, uso da composição | |
BR112018077375A2 (pt) | kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente | |
BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
BR112014027155A2 (pt) | composições de celúlas t deficientes do re-ceptor de células t | |
BR112018067679A2 (pt) | células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso | |
BR112016010025A2 (pt) | molécula de ligação de antígeno contendo região variável de anticorpo modificado | |
BR112019006006A2 (pt) | molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico. | |
Wei et al. | Identifying and targeting tumor-initiating cells in the treatment of breast cancer | |
Ludlow et al. | (−)-Englerin A-evoked cytotoxicity is mediated by Na+ influx and counteracted by Na+/K+-ATPase | |
BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
BR112018008061A2 (pt) | métodos para a cultura de células e kits e aparelhos para os mesmos | |
BR112013022871A2 (pt) | microesferas ocas | |
Guan et al. | Methylcytosine dioxygenase TET3 interacts with thyroid hormone nuclear receptors and stabilizes their association to chromatin | |
BR112013022832A2 (pt) | linhagens de células de baixo teor de fucose e usos das mesmas | |
BR112016011096A2 (pt) | Aplicação de laminina à cultura de célula endotelial da córnea | |
BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
BR112013003850A2 (pt) | buffer de escrita de combinação com medidas de esvaziamento dinamicamente ajustáveis | |
Shen et al. | APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations | |
BR112016028755A2 (pt) | anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo. | |
BRPI0817427A8 (pt) | anticorpo anti-bst2 | |
Gardelli et al. | Differential glycosylation of collagen modulates lung cancer stem cell subsets through β1 integrin‐mediated interactions | |
Guo et al. | The favored mechanism for coping with acute cold stress: upregulation of miR-210 in rats | |
BR112012021326A2 (pt) | anticorpo monoclonal anti-vegf completamente humano, método de preparação e uso do mesmo. | |
BR112016002743A2 (pt) | novo anticorpo de receptor de tslp anti-humana | |
BR112022009290A2 (pt) | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |